2012 Зміст Члени Групи з розробки настанови Відбір клінічних настанов для адаптації Синтез настанови Вступ 1 Передумови 2 Визначення 3 Поширеність Цільова аудиторія

and metformin in treatment-naive patients with type 2 diabetes. Current Medical Research & Opinion

2004;20(6):883–889.

92 Dashora UK, Sibal L, Ashwell SG et al. Insulin glargine in combination with nateglinide in people with

type 2 diabetes: a randomized placebo-controlled trial. Diabetic Medicine 2007;24(4):344–349.

93 Schernthaner G, Grimaldi A, Di MU et al. GUIDE study: double-blind comparison of once-daily gliclazide

MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation 2004;34(8):

535–542.

safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes, Obesity

95 Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to

metformin monotherapy in type 2 diabetic patients. Diabetic Medicine 2001;18(10):828–834.

96 Forst T, Eriksson JW, Strotmann HJ et al. Metabolic effects of mealtime insulin lispro in comparison to

glibenclamide in early type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 2003;111(2):

97–103.

maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis

(UKPDS 73). Journal of Diabetes & its Complications 2006;20(6):395–401.

98 Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive blood glucose control policy in

patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41).

British Medical Journal 2000;320(7246):1373–1378.

99 Van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for type 2 diabetes

mellitus. Cochrane Database of Systematic Reviews 2005;(2):CD003639.

100 Ko GTC, Tsang CC, Ng CW et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Clinical Drug Investigation 2001;21(6):401–408.

101 Goke B, German Pioglitazone Study Group. Effects on blood pressure of the a-glucosidase inhibitor

acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2

diabetes mellitus. Treatments in Endocrinology 2002;1(5):329–336.
Посилання

102 Feinbock C, Luger A, Klingler A et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Diabetes, Nutrition & Metabolism - Clinical & Experimental 2003;16(4):214–221.

103 Hwu CM, Ho LT, Fuh MM et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Diabetes Research & Clinical Practice 2003;60(2):111–118.

104 Phillips P, Karrasch J, Scott R et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Diabetes Care 2003;26(2):269–273.

105 Bachmann W, Petzinna D, Raptis SA et al. Effects on blood pressure of the a-glucosidase inhibitor

acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2

diabetes mellitus. Clinical Drug Investigation 2003;23(10):679–686.

106 Lin BJ, Wu HP, Huang HS et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Journal of Diabetes & its Complications 2003;17(4):179–185.

107 Segal P, Eliahou HE, Petzinna D et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose

compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes

mellitus. Clinical Drug Investigation 2005;25(9):589–595.

108 White TJ, Vanderplas A, Chang E et al. The costs of non-adherence to oral antihyperglycemic medication

in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a

managed care environment. Disease Management and Health Outcomes 2004;12(3):181–188.

109 Quilici S, Chancellor J, Maclaine G et al. Cost-effectiveness of acarbose for the management of impaired

glucose tolerance in Sweden. International Journal of Clinical Practice 2005;59(10):1143–1152.

110 Huang ES, Shook M, Jin L et al. The impact of patient preferences on the cost-effectiveness of intensive

glucose control in older patients with new-onset diabetes. Diabetes Care 2006;29(2):259–264.

111 Johnson JA, Simpson SH, Toth EL et al. Reduced cardiovascular morbidity and mortality associated with

metformin use in subjects with type 2 diabetes. Diabetic Medicine 2005;22(4):497–502.

112 Evans JMM, Ogston SA, EmslieSmith A et al. Risk of mortality and adverse cardiovascular outcomes in

type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia

2006;49(5):930–936.

113 National Institute for Health and Clinical Excellence. Glitazones in the treatment of type 2 diabetes (Review

114 European Medicines Agency. 2007. www.emea.europa.eu

115 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from

cardiovascular causes. New England Journal of Medicine 2007;356(24):2457–2471.

116 Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an

interim analysis. New England Journal of Medicine 2007;357(1):28–38.

117 Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type

2 diabetes mellitus: a meta-analysis of randomized trials. The Journal of the American Medical Association

2007;298(10):1180–1188.

118 Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and

cardiovascular death. Annals of Internal Medicine 2007;147(8):578–581.

119 Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

[see comment]. The Journal of the American Medical Association 2007;298(10):1189–1195.

120 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with

prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

Lancet 2007;370(9593):1129–1136.

121 GlaxoSmithKline. Coronary heart disease outcomes in patients receiving antidiabetic agents. Uxbridge,

Middlesex: GlaxoSmithKline, 2008.
Діабет 2 типу.

122 Richter B, Bandeira-Echtler E, Bergerhoff K et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane

123 Derosa G, Gaddi AV, Piccinni MN et al. Differential effect of glimepiride and rosiglitazone on metabolic

control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Diabetes, Obesity & Metabolism 2006;8(2):197–205.

124 Rosenstock J, Goldstein BJ, Vinik AI et al. Effect of early addition of rosiglitazone to sulphonylurea therapy

in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration

(RESULT) study. Diabetes, Obesity & Metabolism 2006;8(1):49–57.

125 Raskin P, McGill J, Saad MF et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

Diabetic Medicine 2004;21(4):329–335.

126 Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure

independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension

2006;24(10):2047–2055.

127 Vongthavaravat V, Wajchenberg BL, Waitman JN et al. An international study of the effects of

rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Current Medical Research & Opinion

2002;18(8):456–461.

128 St John SM, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on

cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):

2058–2064.

129 Hanefeld M, Patwardhan R, Jones NP et al. A one-year study comparing the efficacy and safety of

rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition Metabolism & Cardiovascular

130 Kerenyi Z, Samer H, James R et al. Combination therapy with rosiglitazone and glibenclamide compared

with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research &

Clinical Practice 2004;63(3):213–223.

131 Derosa G, Gaddi AV, Piccinni MN et al. Antithrombotic effects of rosiglitazone-metformin versus

glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic

syndrome. Pharmacotherapy 2005;25(5):637–645.

132 Baksi A, James RE, Zhou B et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone

to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a

sulphonylurea. Acta Diabetologica 2004;41(2):63–69.

133 Derosa G, D’Angelo A, Ragonesi PD et al. Metabolic effects of pioglitazone and rosiglitazone in patients

with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 2007;37(2):

79–86.

combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with

uncontrolled type 2 diabetes. Diabetes, Obesity & Metabolism 2006;8(6):650–660.

135 Stewart MW, Cirkel DT, Furuseth K et al. Effect of metformin plus roziglitazone compared with

metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine 2006;23(10):

1069–1078.

136 Home PD, Jones NP, Pocock SJ et al. Rosiglitazone RECORD study: glucose control outcomes at

18 months. Diabetic Medicine 2007;24(6):626–634.

137 Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with

inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226–1232.

138 Home PD, Bailey CJ, Donaldson J et al. A double-blind randomized study comparing the effects of

continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people

with type 2 diabetes. Diabetic Medicine 2007;24(6):618–625.

139 Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or

rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Diabetes Care 2006;29(3):554–559.
Посилання

140 Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in

type 2 diabetes. Diabetes Care 2007;30(4):795–800.

141 Richter B, Bandeira-Echtler E, Bergerhoff K et al. Pioglitazone for type 2 diabetes mellitus. Cochrane

142 Dormandy JA. PROactive study. Lancet 2006;367(9405):26–27.

143 Yudkin J.S., Freemantle N. PROactive study. Lancet 2006;367(3504):24–25.

144 PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study.

145 Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in

patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy:

results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical

146 Davidson JA, Perez A, Zhang J. Addition of pioglitazone to stable insulin therapy in patients with poorly

controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes, Obesity &

Metabolism 2006;8(2):164–174.

147 Raz I, Stranks S, Filipczak R et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone

in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an

18-week, randomized, open-label study. Clinical Therapeutics 2005;27(9):1432–1443.

148 Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone

therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2

diabetes. Diabetologia 2005;48(6):1093–1104.

149 Jain R, Osei K, Kupfer S et al. Long-term safety of pioglitazone versus glyburide in patients with recently

diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1388–1395.

150 Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial

infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the

PROactive (PROactive 05) Study. Journal of the American College of Cardiology 2007;49(17):1772–1780.

151 Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid

intima-media thickness in type 2 diabetes: a randomized trial. The Journal of the American Medical

152 Wilcox R, Bousser MG, Betteridge DJ et al. effects of pioglitazone in patients with type 2 diabetes with or

without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In

macroVascular Events 04). Stroke 2007;38(3):865–873.

153 Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Research

& Clinical Practice 2007;76(2):279–289.

154 Czoski-Murray C, Warren E, Chilcott J et al. Clinical effectiveness and cost-effectiveness of pioglitazone

and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

(structured abstract). Health Technology Assessment 2004;8(13)

155 National Institute for Health and Clinical Excellence. Diabetes (type 2) – pioglitazone (replaced by TA63)

(TA21). London: NICE, 2001.

156 Beale S, Bagust A, Shearer AT et al. Cost-effectiveness of rosiglitazone combination therapy for the

treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006;24(Suppl 1):21–34.

157 Tilden DP, Mariz S, O’BryanTear G et al. A lifetime modelled economic evaluation comparing

pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics

2007;25(1):39–54.

158 Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients

with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular

Events): a randomised controlled trial. Lancet 2005;366(9493):1279–1289.

159 Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in

sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628–2635.

160 DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over

30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092–1100.

161 Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30

weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care

2005;28(5):1083–1091.

162 Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and

cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity

163 Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects

with type 2 diabetes: a dose-ranging study. Diabetes Technology & Therapeutics 2005;7(3):467–477.

164 Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally

controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005;143(8):559–569.

165 Secnik BK, Matza LS, Oglesby A et al. Patient-reported outcomes in a trial of exenatide and insulin glargine

for the treatment of type 2 diabetes. Health & Quality of Life Outcomes 2006;4(80).

166 Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in

patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority

study. Diabetologia 2007;50(2):259–267.

167 Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in

suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007;146(7):

477–485.

168 European Medicines Agency. EPARs for authorised medicinal products for human use. Available from:

www.emea.europa.eu. Last accessed on: 19 January 2008.

169 Ray JA, Boye KS, Yurgin N et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the

UK: a model of long-term clinical and cost outcomes. Current Medical Research & Opinion 2007;23(3):

609–622.

oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic

171 Kokic SB. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2

management after secondary oral antidiabetic drug failure. Collegium Antropologicum 2003;27(1):181–187.

172 Olsson PO, Lindstrom T. Combination-therapy with bedtime nph insulin and sulphonylureas gives

similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.

Diabetes & Metabolism 2002;28(4:Pt 1):272–277.

173 Altuntas Y, Ozen B, Ozturk B et al. Comparison of additional metformin or NPH insulin to mealtime

insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes, Obesity

& Metabolism 2003;5(6):371–378.

174 Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Annals of

175 Zargar AH, Masoodi SR, Laway BA et al. Response of regimens of insulin therapy in type 2 diabetes mellitus

subjects with secondary failure. Journal of the Association of Physicians of India 2002;50(5):641–646.

176 Douek IF, Allen SE, Ewings P et al. Continuing metformin when starting insulin in patients with type 2

diabetes: a double-blind randomized placebo-controlled trial. Diabetic Medicine 2005;22(5):634–640.

177 Goudswaard AN, Stolk RP, Zuithoff P et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic

agents? A randomized trial in primary care. Journal of Family Practice 2004;53(5):393–399.

178 Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily

premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28(2):254–259.

179 Stehouwer MH, DeVries JH, Lumeij JA et al. Combined bedtime insulin – daytime sulphonylurea regimen

compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia

rate – a randomised trial. Diabetes/Metabolism Research and Reviews 2003;19(2):148–152.

180 Lechleitner M, Roden M, Haehling E et al. Insulin glargine in combination with oral antidiabetic drugs as

a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wiener Klinische

Wochenschrift 2005;117(17):593–598.

181 Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for economic evaluation of health care

182 Christiansen JS, Vaz JA, Metelko Z. Twice daily biphasic insulin aspart improves postprandial glycaemic

control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with

type 2 diabetes. Diabetes, Obesity & Metabolism 2003;5(6):446–454.

183 Kilo C, Mezitis N, Jain R et al. Starting patients with type 2 diabetes on insulin therapy using once-daily

injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination

with metformin. Journal of Diabetes & its Complications 2003;17(6):307–313.

184 Ceriello A, Del PS, Bue VJ et al. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients

with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk

factors. Journal of Diabetes & its Complications 2007;21(1):20–27.

185 Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in

patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006;(2):CD003287.

186 Boehm BO, Home PD, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70

twice daily: a randomized trial in type 1 and type 2 diabetic patients [erratum appears in Diabetic Medicine.

2002 Sep;19(9):797]. Diabetic Medicine 2002;19(5):393–399.

187 Boehm BO, Vaz JA, Brondsted L et al. Long-term efficacy and safety of biphasic insulin aspart in patients

with type 2 diabetes. European Journal of Internal Medicine 2004;15(8):496–502.

188 Abrahamian H, Ludvik B, Schernthaner G et al. Improvement of glucose tolerance in type 2 diabetic

patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). Hormone &

Metabolic Research 2005;37(11):684–689.

189 Schernthaner G, Kopp HP, Ristic S et al. Metabolic control in patients with type 2 diabetes using Humalog